2022
In with the old, in with the new: machine learning for time to event biomedical research
Danciu I, Agasthya G, Tate JP, Chandra-Shekar M, Goethert I, Ovchinnikova OS, McMahon BH, Justice AC. In with the old, in with the new: machine learning for time to event biomedical research. Journal Of The American Medical Informatics Association 2022, 29: 1737-1743. PMID: 35920306, PMCID: PMC9471708, DOI: 10.1093/jamia/ocac106.Peer-Reviewed Original ResearchPeriods of Homelessness Linked to Higher VACS Index Among HIV-Positive People Who Use Drugs
Reddon H, Socias ME, Justice A, Cui Z, Nosova E, Barrios R, Fairbairn N, Marshall BDL, Milloy M. Periods of Homelessness Linked to Higher VACS Index Among HIV-Positive People Who Use Drugs. AIDS And Behavior 2022, 26: 1739-1749. PMID: 35064852, PMCID: PMC9150923, DOI: 10.1007/s10461-021-03524-1.Peer-Reviewed Original ResearchMeSH KeywordsAgingCohort StudiesDisease ProgressionHIV InfectionsHumansIll-Housed PersonsProspective StudiesVeteransConceptsHIV disease progressionART adherenceDisease progressionAntiretroviral therapyVeterans Aging Cohort Study (VACS) IndexVACS Index scoreSignificant risk factorsHIV-positive peopleVACS IndexCause mortalityProspective cohortRisk factorsMortality riskIndex scoreStudy indicesAdherenceProgressionLongitudinal relationshipHIVImpact of homelessnessPWUDUnregulated drugsAssociationDrugsFuture studies
2018
AUDIT‐C and ICD codes as phenotypes for harmful alcohol use: association with ADH1B polymorphisms in two US populations
Justice AC, Smith RV, Tate JP, McGinnis K, Xu K, Becker WC, Lee K, Lynch K, Sun N, Concato J, Fiellin DA, Zhao H, Gelernter J, Kranzler HR, Program O. AUDIT‐C and ICD codes as phenotypes for harmful alcohol use: association with ADH1B polymorphisms in two US populations. Addiction 2018, 113: 2214-2224. PMID: 29972609, PMCID: PMC6226338, DOI: 10.1111/add.14374.Peer-Reviewed Original Research
2015
Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion
Butt AA, Yan P, Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion. JAMA Internal Medicine 2015, 175: 178-185. PMID: 25485735, PMCID: PMC5017246, DOI: 10.1001/jamainternmed.2014.6502.Peer-Reviewed Original ResearchConceptsDiagnosis of cirrhosisLiver fibrosis progressionHepatic decompensation eventsDevelopment of cirrhosisFibrosis progressionHCV controlHepatic decompensationDecompensation eventsLiver fibrosisNegative HCV antibody test resultPositive HCV RNA test resultLower mean body mass indexHCV antibody test resultHCV RNA test resultsNational Veterans Affairs databaseHepatitis C virus infectionMean body mass indexHigher serum aminotransferase levelsHCV Infected VeteransRNA test resultsC virus infectionFIB-4 scoreFibrosis-4 indexSerum aminotransferase levelsMonths of follow
2012
Comorbid Diabetes and the Risk of Progressive Chronic Kidney Disease in HIV-Infected Adults
Medapalli RK, Parikh CR, Gordon K, Brown ST, Butt AA, Gibert CL, Rimland D, Rodriguez-Barradas MC, Chang CC, Justice AC, He JC, Wyatt CM. Comorbid Diabetes and the Risk of Progressive Chronic Kidney Disease in HIV-Infected Adults. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2012, 60: 393-399. PMID: 22592587, PMCID: PMC3392432, DOI: 10.1097/qai.0b013e31825b70d9.Peer-Reviewed Original ResearchConceptsCKD risk factorsTraditional CKD risk factorsRisk factorsBaseline eGFRChronic kidney disease progressionProgressive chronic kidney diseaseChronic kidney diseaseKidney disease progressionGlomerular filtration rateMean baseline eGFRRisk of CKDRate of progressionCox proportional hazardsVeterans Healthcare AdministrationUse of cARTBaseline HIVCKD progressionComorbid diabetesAdjunctive therapyDiabetes statusGlycemic controlKidney diseaseProgressive CKDComplex comorbiditiesFiltration rate
2011
The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J, Collaboration F. The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine 2011, 13: 89-97. PMID: 21819529, PMCID: PMC4539012, DOI: 10.1111/j.1468-1293.2011.00940.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Therapy, CombinationDrug UsersFemaleHIV InfectionsHumansMaleMiddle AgedOdds RatioProportional Hazards ModelsRisk FactorsRNA, ViralSubstance Abuse, IntravenousViral LoadYoung AdultConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countDisease progressionCell countCART initiationAntiretroviral therapyHigher baseline HIV viral loadLower baseline CD4 cell countBaseline HIV viral loadSpecific causesART Cohort CollaborationLiver-related deathHIV viral loadHIV-positive individualsRisk of deathCause of deathDrug use historyCohort CollaborationCohort studyCumulative incidenceHazard ratioHIV diseaseClinical AIDSPrior diagnosisWhen to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
Cain L, Logan R, Robins J, Sterne J, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher H, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan M. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals Of Internal Medicine 2011, 154: 509-15. PMID: 21502648, PMCID: PMC3610527, DOI: 10.7326/0003-4819-154-8-201104190-00001.Peer-Reviewed Original ResearchConceptsCD4 cell countCombined end pointHazard ratioCell countCells/LAntiretroviral therapyCells/L.CD4 cell count thresholdBaseline CD4 cell countEnd pointVeterans Health Administration systemInitiation of cARTThreshold CD4 countCorresponding hazard ratiosMortality hazard ratioAIDS-free survivalProspective observational dataHIV-CAUSAL CollaborationMost clinical guidelinesHealth Administration systemUse of CD4Marginal structural modelsCell count thresholdCART initiationDynamic marginal structural models
2010
Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value?
Braithwaite RS, Fiellin DA, Nucifora K, Bryant K, Roberts M, Kim N, Justice AC. Evaluating Interventions to Improve Antiretroviral Adherence: How Much of an Effect Is Required for Favorable Value? Value In Health 2010, 13: 535-542. PMID: 20345544, PMCID: PMC3032536, DOI: 10.1111/j.1524-4733.2010.00714.x.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionNonadherent patientsAdherence interventionsRelative riskRisk factorsAntiretroviral therapy adherence interventionsEffect sizeNonadherence risk factorsBehavioral risk factorsHIV careAntiretroviral adherencePatientsNonadherenceSocietal perspectiveIncremental costIntervention costsSmall effect sizesLife expectancyInterventionRisk reductionPlausible effect sizesTowards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkers
Justice A, McGinnis K, Skanderson M, Chang C, Gibert C, Goetz M, Rimland D, Rodriguez‐Barradas M, Oursler K, Brown, Braithwaite R, May M, Covinsky K, Roberts, Fultz S, Bryant K, Team F. Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkers. HIV Medicine 2010, 11: 143-151. PMID: 19751364, PMCID: PMC3077949, DOI: 10.1111/j.1468-1293.2009.00757.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAIDS-Related Opportunistic InfectionsAnemiaAnti-HIV AgentsBiomarkersCause of DeathCD4 Lymphocyte CountCohort StudiesConfidence IntervalsDisease ProgressionDrug Therapy, CombinationFemaleHepatitis, Viral, HumanHIV InfectionsHIV Long-Term SurvivorsHumansLiver CirrhosisMaleMiddle AgedRNA, ViralSeverity of Illness IndexSubstance-Related DisordersSurvival AnalysisConceptsCombination antiretroviral therapyVeterans Aging Cohort StudyHIV biomarkersVACS IndexHIV infectionSurvival intervalAging Cohort StudyShorter survival intervalAntiretroviral therapyCause mortalityCohort studyHIV markersPrognostic indexAIDS conditionsChronic inflammationMortality riskHIVSubstance abuseBiomarkersMortalityBiomarker groupsComplete dataSimilar intervalsInfectionFurther validation
2009
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements
Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte A, Force L, Gill J, Harris R, Hogg R, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne J, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009, 23: 2199-2208. PMID: 19779320, PMCID: PMC3122149, DOI: 10.1097/qad.0b013e3283305a00.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyCD4 cell countHIV-1-infected patientsHIV-1 RNAViral loadCART initiationCell countStart of cARTHIV-1 RNA measurementsART Cohort CollaborationMedian CD4 cellPredictors of AIDSRates of AIDSImportant prognostic factorPrognosis of patientsCohort CollaborationSubsequent AIDSAntiretroviral therapyHIV cohortCD4 cellsPrognostic factorsPrognostic importanceCopies/PatientsAIDSTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
Sterne J, May M, Costagliola D, de Wolf F, Phillips A, Harris R, Funk M, Geskus R, Gill J, Dabis F, Miró J, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole S. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. The Lancet 2009, 373: 1352-1363. PMID: 19361855, PMCID: PMC2670965, DOI: 10.1016/s0140-6736(09)60612-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Administration ScheduleEuropeFemaleHIV InfectionsHIV-1HumansKaplan-Meier EstimateMaleMiddle AgedNorth AmericaPatient SelectionPractice Guidelines as TopicProportional Hazards ModelsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsHIV-1-infected patientsCombination antiretroviral therapyCD4 cell countAntiretroviral therapyCombination therapyCohort studyCell countCD4 cell count rangeCD4 cell count thresholdAntiretroviral-naive patientsProspective cohort studyHIV Cohort StudyRates of AIDSStart of treatmentHigh mortality rateAbsence of treatmentTiming of initiationDeath eventsCell count thresholdTherapy groupImmediate initiationPatientsMortality rateTherapyAIDS
2008
Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.
Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Annals Of Internal Medicine 2008, 148: 178-85. PMID: 18252681, PMCID: PMC3124094, DOI: 10.7326/0003-4819-148-3-200802050-00004.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyViral loadHIV treatmentEarly treatmentEarly initiationLife expectancyVeterans Aging Cohort StudyChronic HIV infectionCombination antiretroviral therapyEarly treatment initiationAging Cohort StudyTherapy-related toxicityAge 40 yearsQuality-adjusted life expectancyAge 30 yearsBase-case analysisCohort studyHIV infectionTreatment initiationCopies/Current recommendationsLate treatmentImportant harmsTherapyTreatment
2007
Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity?
Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, Bryant K, Justice AC. Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity? Clinical Infectious Diseases 2007, 45: 1593-1601. PMID: 18190322, PMCID: PMC3687553, DOI: 10.1086/523577.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusCD4 cell countPatterns of comorbidityHIV infectionHIV statusCell countHIV severityOlder human immunodeficiency virusPrimary care guidelinesClinical Modification codesCells/Pulmonary diseaseComorbid conditionsMultivariable analysisViral loadCare guidelinesImmunodeficiency virusComorbiditiesInternational ClassificationMultimorbidityInfectionPresence of conditionsVeteransAgeDisease
2005
The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy
d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M. The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy. JAMA Internal Medicine 2005, 165: 416-423. PMID: 15738371, DOI: 10.1001/archinte.165.4.416.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapyAIDS eventsAntiretroviral therapyViral etiologyRate of declineAntiretroviral-naive individualsRates of AIDSIncidence of AIDSCohort CollaborationCD4 countMonths 0Different etiologiesFungal etiologyChanging IncidenceHAARTPoisson regressionEtiologyIncidenceRNA levelsAIDSViral eventsTherapyMonths
2004
Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy
Raffanti SP, Fusco JS, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2004, 37: 1147-1154. PMID: 15319674, DOI: 10.1097/01.qai.0000136738.24090.d0.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCopies/mLBaseline HIV-1 RNA levelsNew AIDSCopies/Moderate viremiaRNA levelsPlasma HIV-1 RNAAIDS-defining diagnosisAntiretroviral therapy historyActive antiretroviral therapyUnited States cohortHIV-1 RNACells/Proportional hazards modelCD4 count changesImmunologic deteriorationAntiretroviral therapyCD4 countPrior AIDSUndetectable viremiaViral suppressionImmunologic statusHIV infectionClinical benefitDisease progression in HIV-infected patients treated with stavudine vs. zidovudine
Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM, Team T. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine. Journal Of Clinical Epidemiology 2004, 57: 89-97. PMID: 15019015, DOI: 10.1016/s0895-4356(03)00245-2.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDatabases, FactualDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHIV InfectionsHIV Wasting SyndromeHumansProportional Hazards ModelsProspective StudiesReverse Transcriptase InhibitorsStavudineZidovudineConceptsCells/microLDisease progressionLandmark analysisCox proportional hazards modelEvent-free survivalHIV-1 patientsHIV-1 RNAProportional hazards modelPrevious AIDSStavudine treatmentCD4 countHIV infectionInhibitor useCombination therapyUnadjusted analysesObservational studyHIV-1U.S. cohortHazards modelPatientsZidovudineStavudineNew casesNRTIsProgression
2003
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies
Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. The Lancet 2003, 362: 679-686. PMID: 12957089, DOI: 10.1016/s0140-6736(03)14229-8.Peer-Reviewed Original ResearchConceptsCells/microLHIV-1 RNACopies/mLCD4 countHazard ratioHIV-1Current CD4 cell countPotent antiretroviral therapyCD4 cell countTreatment-naive patientsYears of followActive antiretroviral treatmentHigh-risk stratumSubsequent disease progressionLow-risk stratumProbability of progressionBaseline CD4Antiretroviral therapyCohort studyAntiretroviral treatmentMonth 6Viral loadClinical progressionPrognostic importanceProspective study
1998
Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy
Weiss M, Rodby R, Justice A, Hricik D, Group T. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Kidney International 1998, 54: 193-202. PMID: 9648079, DOI: 10.1046/j.1523-1755.1998.00982.x.Peer-Reviewed Original ResearchConceptsC-reactive proteinProtein-bound pentosidineDiabetic nephropathyInterleukin-6Serum creatinineFree pentosidineMonocyte/macrophage activationAdvanced glycation end product pentosidineBaseline disease activityDegree of proteinuriaSubgroup of patientsImmune activation responseProportional hazards methodsDisease activityInflammatory markersCreatinine levelsRenal functionDiabetes mellitusSerum levelsDiabetic complicationsProgression rateGroup trialsHazards methodsMacrophage activationNephropathy